Skip to content
DataLookout
Menu

STARNCT04068753

Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 21 versions: 21 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 32 words
    • Primary completion date changed from estimate of Dec 2026 to Aug 6, 2026
    • Study completion date: Jul 2027 to Aug 2027
  2. Notable Primary completion date: Dec 2025 to Dec 2026v20
  3. Minor Primary completion date: Sep 2025 to Dec 2025v19
  4. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 4 of 4 sites
    v18
  5. Minor Primary completion date: Jul 2025 to Sep 2025v17
Show 15 earlier versionsHide 15 earlier versions
  1. Minor Site details revised at 1 of 4 sitesv16
  2. Minor Site details revised at 1 of 4 sitesv15
  3. Notable Primary completion date: Jul 2024 to Jul 2025
    • Study completion date: Jul 2026 to Jul 2027
    v14
  4. Notable Eligibility criteria expanded, about 157 words
    • Site details revised at 1 of 4 sites
    v13
  5. Notable Primary completion date: Jul 2023 to Jul 2024
    • Study completion date: Jul 2025 to Jul 2026
    v12
  6. Minor Study sites revised (4)v11
  7. Minor Site details revised at 1 of 4 sitesv10
  8. Minor Site details revised at 1 of 4 sitesv9
  9. Minor Site details revised at 2 of 4 sitesv8
  10. Notable Primary completion date: Jul 2021 to Jul 2023v7
  11. Minor Study sites: 3 to 4v6
  12. Minor Site contacts updated at 1 of 3 sitesv5
  13. Notable Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Study sites: 1 to 3
    • Primary completion date: Jun 2021 to Jul 2021
    • Study completion date: Jun 2025 to Jul 2025
    • Start date changed from estimate of Feb 2020 to Feb 26, 2020
  14. Minor Study description shortened, about 18 wordsv3
  15. Notable Start date: Sep 2019 to Feb 2020v2 Show 6 more changesShow less
    • Eligibility criteria revised
    • Study completion date: Dec 2024 to Jun 2025
    • Interventions: Niraparib (Drug), TSR-042 (Drug) to Niraparib (Drug), dostarlimab (Drug)
    • Secondary endpoints: details revised at 4 of 4 entries
    • Study description revised
    • Study title revised
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Proportion of patients with response to treatment
Timeframe: 1 year

Secondary (4)

Number of patients who experience toxicity
Duration of patients with response
Progression free survival
Overall survival

Arms and interventions

Niraparib + dostarlimabExperimental

Drugs: Niraparib, dostarlimab

Sites

4 sites in 1 country